Kissei Pharmaceutical And Wakamoto Pharmaceutical Co-Promote Salagen
This article was originally published in PharmAsia News
Executive Summary
Kissei Pharmaceutical and Wakamoto Pharmaecutical signed an agreement May 2 to co-promote Kissei's Salagen (pilocarpine), a drug used to treat dryness of the mouth and throat that may occur after radiation treatment for cancer of the head and neck, and to patients with Sjogren's syndrome. Kissei obtained the drug's exclusive development and marketing right in Japan from MGI Pharma, a subsidiary of Eisai. According to the agreement, Kissei and Wakamoto will promote the drug to assigned medical facilities, but Kissei will continue to solely handle manufacturing, marketing and distribution. (Click here for more - Japanese language
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.